Key result
CNS metastases in pediatric Ewing sarcoma linked to poor survival, with median OS of ~5 months.
Why the study?
Metastatic CNS involvement is rare in pediatric primary extracranial Ewing sarcoma, and its incidence and clinical course are not well described.
Observational (n=6)
No
CNS metastases in pediatric Ewing sarcoma are rare and associated with a very poor prognosis, with median overall survival of 4.6 months after detection.
Answers are grounded in this paper and cite their sources.
CNS metastases portend dismal survival in pediatric Ewing sarcoma; hypothesis-generating for prospective therapeutic trials.
Metastatic central nervous system (CNS) involvement is rare in pediatric primary extracranial Ewing sarcoma (ES). We describe the incidence and course of 6 patients with extracranial ES who developed metastatic CNS lesions treated at a single institution. The median time to CNS disease detection was 16.3 months (10.0-28.3 months). Event-free and overall survival after CNS disease detection were 1.9 months (0.4 to 10.3 months) and 4.6 months (1.1 to 50.9 months), respectively. One patient was alive at the time of analysis. Clinical status and ability to obtain disease control should be considered when making decisions regarding aggressive interventions in these patients with poor prognosis.
No takes yet. Share an insight, caveat, or question.
Slatnick et al. (2024) conducted an observational in Pediatric primary extracranial Ewing sarcoma with metastatic CNS lesions (n=6). Central nervous system metastases was evaluated on Event-free and overall survival after CNS disease detection. In pediatric patients with extracranial Ewing sarcoma, central nervous system metastases carried a poor prognosis, with median event-free and overall survival of 1.9 and 4.6 months, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: